IPO - Profile


Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). We are developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation (FAO), and may increase More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$15.00 6,250,000 Positive High 29.73%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 08 Apr, 2021

Offer 09 Apr, 2021

Look Ahead

Lock Up Expiry Oct 09, 2021

IPO Terms

Offer Price $15.00
Offer Size 6M

Market Sentiments

Stock Price